Abstract
1 Eighteen our of twenty non-significant placebo controlled trials are shown to have trends favouring imipramine and are consistent with a further ten significant at 0.05. 2 The problems of falsely positive and falsely negative results are discussed. A plea is made to medical journal editors to publish 'negative' or null difference trials by title only; rather than not at all.